Chemically-Induced Disorders: Clinical Trials

9,215 trials for Chemically-Induced Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5620 completed, 1046 unknown, 1000 recruiting, 455 terminated. 4023 Not applicable, 1715 Phase 2, 903 Phase 1, 704 Phase 3, 568 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable4023Completed 2391, Recruiting 519, Unknown 449, Not yet recruiting 190, Active not recruiting 172, Terminated 138, Withdrawn 104, Enrolling by invitation 45, Suspended 15
Phase 21715Completed 1117, Recruiting 148, Unknown 140, Terminated 119, Withdrawn 91, Not yet recruiting 58, Active not recruiting 33, Suspended 6, Enrolling by invitation 3
Phase 1903Completed 611, Recruiting 75, Unknown 72, Terminated 54, Withdrawn 40, Active not recruiting 26, Not yet recruiting 24, Enrolling by invitation 1
Phase 3704Completed 456, Unknown 84, Terminated 55, Recruiting 48, Withdrawn 27, Active not recruiting 14, Not yet recruiting 14, Enrolling by invitation 3, Suspended 3
Phase 4568Completed 364, Unknown 54, Terminated 52, Recruiting 39, Withdrawn 32, Not yet recruiting 13, Active not recruiting 8, Enrolling by invitation 4, Suspended 2
Early Phase 1166Completed 93, Recruiting 20, Terminated 14, Not yet recruiting 12, Unknown 11, Active not recruiting 8, Withdrawn 6, Enrolling by invitation 1, Suspended 1

Follow Chemically-Induced Disorders: new trials by email Literature Review of Chemically-Induced Disorders trials Research Report on Chemically-Induced Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use
Phase 2WithdrawnUniversity of Maryland, Baltimore2050-01-012021-04-19
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
WithdrawnMassachusetts General Hospital2030-01-012026-01-16
The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veterans
Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) - Alcohol Problems, Post-Traumatic Stress Disorder
Not applicableNot yet recruitingVA Office of Research and Development292028-07-032025-11-19
Dynamic Treatment Regimes for Opioid Use Disorder
Medication for opioid use disorder, psychotherapy - Opioid Use Disorder
Phase 2Not yet recruitingBrigham and Women's Hospital752028-07-012025-11-04
Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
Integrated care - Opioid Use Disorder, HIV
Not applicableNot yet recruitingVA Office of Research and Development602028-04-032026-04-24
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease
AcamproSync - Alcohol Use Disorder, Alcohol Associated Liver Disease
Not applicableNot yet recruitingYale University502027-10-012026-04-28
Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial
nicotine patch, nicotine gum, nicotine lozenge, varenicline, bupropion, Multi-target Contingency Management, Teamlet booster - Tobacco Use Disorder/Cigarette Smoking, HIV
Phase 4Not yet recruitingYale University7942027-09-302026-09-23
Self-administered Neurostimulation Intervention for Firefighter Traumatic Stress to Reduce Alcohol Use: Pilot Study
Transcutaneous auricular neurostimulation (tAN), Active Sham - Posttraumatic Stress Symptoms, Heavy Alcoholic Consumption
Not applicableNot yet recruitingUniversity of Cincinnati202027-09-012026-10-09
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07
eTSF for Latinx Young Adults With Alcohol Use Disorder
eTSF, Educational materials - Alcohol Use Disorder (AUD)
Not applicableNot yet recruitingTulane University402027-08-012026-10-13
Adapting a Telehealth Intervention for Suicide Prevention Among Patients With Alcohol Use Disorder in Tanzania
IDEAS-AUD - Alcohol Use Disorder, Suicide Prevention
Not applicableNot yet recruitingDuke University302027-08-012026-03-17
MedSMA℞T Mobile ED
MedSMA℞T Mobile - Opiate-Related Disorders, Opiate Use Disorder
Not applicableNot yet recruitingOlufunmilola Abraham2442027-08-012026-10-09
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal
Phase 1 / Phase 2Not yet recruitingClive Michelsen602027-07-012026-10-13
Permanent Supportive Housing Overdose Prevention+ Study
TA Intervention - Overdose, Substance Use
Not applicableNot yet recruitingNYU Langone Health29402027-07-012026-05-06
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
Development of a Mobile Health Intervention to Support Functioning of Veterans With Substance Use Disorders
METS4Vets - Substance Use
Not applicableNot yet recruitingVA Office of Research and Development302027-06-012026-10-05
Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment
Opioid Use Disorder
Not yet recruitingTools4Patient2952027-06-012026-10-01
A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerging Adults
Large language model-based chatbot brief alcohol intervention session - Alcohol Use Disorder
Not applicableNot yet recruitingMassachusetts General Hospital202027-06-012025-10-22
TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)
TMS Low-Dose, TMS High-Dose - Alcohol Use Disorder, Opioid Use Disorder
Not applicableRecruitingWashington State University602027-06-012026-05-29
Substance Use Prevention for Recently Displaced Adults - SUPRA (R33) RCT
Acceptance and Commitment Therapy, Attention Control - Prevention, Substance Use
Not applicableNot yet recruitingBoston Medical Center1442027-04-012026-06-29

Showing 20 of 9215. Sign in to see all of them.

Narrower conditions

Substance-Related Disorders (2231)  ·  Alcoholism (1666)  ·  Opioid-Related Disorders (1470)  ·  Tobacco Use Disorder (1022)  ·  Marijuana Abuse (560)  ·  Drug-Related Side Effects and Adverse Reactions (443)  ·  Cocaine-Related Disorders (416)  ·  Smoking Cessation (338)  ·  Bites and Stings (322)  ·  Behavior, Addictive (305)  ·  Depression (288)  ·  Smoking (286)  ·  Alcohol Drinking (255)  ·  Cardiotoxicity (255)  ·  Stress Disorders, Post-Traumatic (239)

Broader conditions

Mental Disorders (7085)  ·  Substance-Related Disorders (5175)  ·  Behavior (2126)  ·  Alcohol-Related Disorders (1959)  ·  Narcotic-Related Disorders (1601)  ·  Pathological Conditions, Signs and Symptoms (1588)  ·  Pathologic Processes (955)  ·  Poisoning (817)  ·  Wounds and Injuries (786)  ·  Signs and Symptoms (782)  ·  Drug-Related Side Effects and Adverse Reactions (648)  ·  Nervous System Diseases (647)  ·  Neurologic Manifestations (592)  ·  Health Behavior (517)

Interventions

Ethanol (229)  ·  Buprenorphine (190)  ·  Therapeutics (174)  ·  Naltrexone (160)  ·  Tobacco Use Cessation Devices (139)  ·  Varenicline (123)  ·  Buprenorphine, Naloxone Drug Combination (122)  ·  nabiximols (116)  ·  Nicotine (115)  ·  Cognitive Behavioral Therapy (112)  ·  Motivational Interviewing (100)  ·  Dronabinol (99)  ·  Sugars (97)  ·  Bupropion (77)  ·  Standard of Care (69)

Sponsors

Yale University (357)  ·  National Institute on Drug Abuse (NIDA) (331)  ·  Medical University of South Carolina (155)  ·  Johns Hopkins University (150)  ·  VA Office of Research and Development (146)  ·  New York State Psychiatric Institute (138)  ·  University of Pennsylvania (137)  ·  University of California, Los Angeles (106)  ·  University of California, San Francisco (98)  ·  Centre for Addiction and Mental Health (79)  ·  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (79)  ·  Massachusetts General Hospital (74)  ·  Brown University (72)  ·  University of Wisconsin, Madison (71)  ·  University of Washington (69)

Countries

United States (5694)  ·  France (400)  ·  Canada (368)  ·  China (262)  ·  Germany (184)  ·  United Kingdom (182)  ·  Spain (166)  ·  Turkey (Türkiye) (131)  ·  Sweden (106)  ·  Denmark (98)  ·  Egypt (88)  ·  Norway (86)  ·  Switzerland (84)  ·  Netherlands (82)  ·  Italy (80)

Top investigators

Walter Ling, M.D. (35)  ·  Warren Bickel, Ph.D. (22)  ·  Dorothy Hatsukami, Ph.D. (19)  ·  James Zacny, Ph.D. (17)  ·  Elisabeth Kruse, PhD (16)  ·  Elliot Stein, Ph.D. (14)  ·  Mark Greenwald, PhD (13)  ·  Thomas R Kosten, M.D. (12)  ·  Lorenzo Leggio, M.D. (11)  ·  Herbert Kleber, M.D. (10)  ·  Kenneth Silverman, Ph.D. (10)  ·  Eric C. Strain, MD (9)  ·  Eugene Somoza, M.D., Ph.D. (9)  ·  Frances R Levin, M.D. (9)

Results publications

PMID 37142273, PMID 37230961, PMID 40342086, PMID 37335995, PMID 39868569, PMID 34611902, PMID 25630964, PMID 29912955, PMID 34231914, PMID 37795783, PMID 33348423, PMID 42560883, PMID 22700038, PMID 33605440, PMID 35287034, PMID 36063082, PMID 39101506, PMID 41085955, PMID 25911999, PMID 25938124, PMID 35420700, PMID 37393415, PMID 40833692, PMID 20707781, PMID 22339949, PMID 24896818, PMID 25227627, PMID 26582720, PMID 27342744, PMID 30865232, PMID 31723056, PMID 32086791, PMID 32280263, PMID 32608505, PMID 32628945, PMID 33079196, PMID 33788162, PMID 33884617, PMID 34242666, PMID 34255068, PMID 34295186, PMID 34532852, PMID 36208817, PMID 37011138, PMID 37023858, PMID 37657559, PMID 38236223, PMID 39240566, PMID 42423707, PMID 10776874

NIH funding

2025 (18), R01DA008391 (17), P50DA009236 (15), P50DA009262 (13), 2015 (12), 2023 (12), P50DA009241 (12), P50DA018197 (12), 2019 (11), 2008 (10), 2009 (10), P50DA027840 (10), 2014 (9), 2017 (9), 2016 (8)